Compositions and methods for treating gluten intolerance and disorders arising therefrom

Patent metadata

Field	Value
Publication number	US-10857214-B2
Application number	US-201615382560-A
Country	US
Kind code	B2
Filing date	Dec 16, 2016
Priority date	Dec 16, 2015
Publication date	Dec 8, 2020
Grant date	Dec 8, 2020

Abstract

The invention described herein relates to methods and compositions for treatment of one or more symptoms of gluten intolerance and related conditions (e.g., celiac disease and gluten sensitivity) by administration of a pharmaceutical composition comprising one or more Nepenthes enzymes.

First claim

What is claimed is:

1. A method for attenuating one or more symptoms of gluten intolerance in a patient in need thereof, which method comprises administering to the patient an effective amount of a pharmaceutical composition comprising neprosin or a variant thereof so as to cleave gluten into non-antigenic peptides, thereby attenuating said symptoms.

2. The method of claim 1 , wherein the one or more symptoms are selected from the group consisting of intestinal inflammation, villous atrophy, intraepithelial lymphocytosis.

3. The method of claim 1 , wherein the composition comprises neprosin and nepenthesin I and/or nepenthesin II at a ratio of about 1:4 (neprosin:nepenthesin).

4. The method of claim 1 , wherein the pharmaceutical composition is orally administered prior to, during, or immediately after consumption of a gluten-containing food.

5. The method of claim 1 , wherein the patient suffers from a disease selected from the group consisting of celiac disease, attention deficit hyperactivity disorder, autism, rheumatoid arthritis, fibromyalgia, nutrient malabsorption, and dermatitis herpetiformis.

6. The method of claim 1 , wherein the pharmaceutical composition is a sustained-release formulation.

7. The method of claim 1 , wherein the pharmaceutical composition comprises an extract of Nepenthes pitcher fluid comprising neprosin.

8. The method of claim 1 , wherein the neprosin or variant thereof is a recombinant protein.

9. The method of claim 1 , wherein the pharmaceutical composition is between about pH 5 and about pH 8.

10. The method of claim 1 , wherein the pharmaceutical composition comprises neprosin.

11. The method of claim 1 , wherein the pharmaceutical composition further comprises nepenthesin I or a variant thereof.

12. The method of claim 1 , wherein the pharmaceutical composition further comprises nepenthesin II or a variant thereof.

13. The method of claim 1 , wherein the pharmaceutical composition further comprises nepenthesin I or a variant thereof and nepenthesin II or a variant thereof.

14. The method of claim 1 , wherein the effective amount comprises a total daily protein ingested by the patient to enzyme ratio of between about 1000:1 and about 15000:1.

Assignees

• Codexis Inc

Inventors

• Schriemer David C
• Rey Martial

Classifications

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• C12Y304/23012

  Nepenthesin (3.4.23.12) · CPC title

• A61K38/48

  acting on peptide bonds (3.4) · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title